The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes

被引:93
作者
Giotopoulos, G.
Symonds, R. P.
Foweraker, K.
Griffin, M.
Peat, I.
Osman, A.
Plumb, M.
机构
[1] Univ Leicester, Leicester Royal Infirm, Dept Canc Studies & Mol Med, Leicester LE1 5WW, Leics, England
[2] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England
[3] Nottingham Univ Hosp NHS Trust, Dept Oncol, ICT Serv, Nottingham, England
关键词
breast cancer; radiation injury; TGF beta 1; XRCC1; fibrosis; telangiectasia;
D O I
10.1038/sj.bjc.6603637
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between late normal tissue radiation injury phenotypes in 167 breast cancer patients treated with radiotherapy and: (i) radiotherapy dose (boost); (ii) an early acute radiation reaction and (iii) genetic background was examined. Patients were genotyped at single nucleotide polymorphisms (SNPs) in eight candidate genes. An early acute reaction to radiation and/or the inheritance of the transforming growth factor-beta 1 (TGF beta 1 - 509T) SNP contributed to the risk of fibrosis. In contrast, an additional 15 Gy electron boost and/or the inheritance of X-ray repair cross-complementing 1 (XRCC1) (R399Q) SNP contributed to the risk of telangiectasia. Although fibrosis, telangiectasia and atrophy, all contribute to late radiation injury, the data suggest that they have distinct underlying genetic and radiobiological causes. Fibrosis risk is associated with an inflammatory response (an acute reaction and/or TGF beta 1), whereas telangiectasia is associated with vascular endothelial cell damage (boost and/or XRCC1). Atrophy is associated with an acute response, but the genetic predisposing factors that determine the risk of an acute response or atrophy have yet to be identified. A combined analysis of two UK breast cancer patient studies shows that 8% of patients are homozygous (TT) for the TGFb1 (C-509T) variant allele and have a 15-fold increased risk of fibrosis following radiotherapy (95% confidence interval: 3.76 - 60.3; P = 0.000003) compared with (CC) homozygotes.
引用
收藏
页码:1001 / 1007
页数:7
相关论文
共 45 条
[31]   Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis [J].
McDermott, DH ;
Halcox, JPJ ;
Schenke, WH ;
Waclawiw, MA ;
Merrell, MN ;
Epstein, N ;
Quyyumi, AA ;
Murphy, PM .
CIRCULATION RESEARCH, 2001, 89 (05) :401-407
[32]  
Moullan N, 2003, CANCER EPIDEM BIOMAR, V12, P1168
[33]   Late radiation-related fibrosis: Pathogenesis, manifestations, and current management [J].
O'Sullivan, B ;
Levin, W .
SEMINARS IN RADIATION ONCOLOGY, 2003, 13 (03) :274-289
[34]   LATE EFFECTS TOXICITY SCORING - THE SOMA SCALE [J].
PAVY, JJ ;
DENEKAMP, J ;
LETSCHERT, J ;
LITTBRAND, B ;
MORNEX, F ;
BERNIER, J ;
GONZALESGONZALES, D ;
HORIOT, JC ;
BOLLA, M ;
BARTELINK, H .
RADIOTHERAPY AND ONCOLOGY, 1995, 35 (01) :11-15
[35]  
Quarmby S, 1999, INT J CANCER, V82, P385, DOI 10.1002/(SICI)1097-0215(19990730)82:3<385::AID-IJC12>3.3.CO
[36]  
2-X
[37]   Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients [J].
Quarmby, S ;
Fakhoury, H ;
Levine, E ;
Barber, J ;
Wylie, J ;
Hajeer, AH ;
West, C ;
Stewart, A ;
Magee, B ;
Kumar, S .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2003, 79 (02) :137-143
[38]   EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA-1 IN MOUSE SKIN DURING THE ACUTE-PHASE OF RADIATION-DAMAGE [J].
RANDALL, K ;
COGGLE, JE .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1995, 68 (03) :301-309
[39]   HEPATIC EXPRESSION OF MATURE TRANSFORMING GROWTH-FACTOR-BETA-1 IN TRANSGENIC MICE RESULTS IN MULTIPLE TISSUE LESIONS [J].
SANDERSON, N ;
FACTOR, V ;
NAGY, P ;
KOPP, J ;
KONDAIAH, P ;
WAKEFIELD, L ;
ROBERTS, AB ;
SPORN, MB ;
THORGEIRSSON, SS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) :2572-2576
[40]   Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom [J].
Shanley, Susan ;
McReynolds, Kate ;
Ardern-Jones, Audrey ;
Ahern, Roger ;
Fernando, Indrajit ;
Yarnold, John ;
Evans, Gareth ;
Eccles, Diana ;
Hodgson, Shirley ;
Ashley, Sue ;
Ashcroft, Linda ;
Tutt, Andrew ;
Bancroft, Elizabeth ;
Short, Susan ;
Smith, Ian ;
Gui, Gerald ;
Barr, Lester ;
Baildam, Andrew ;
Howell, Anthony ;
Royle, Gavin ;
Pierce, Lori ;
Easton, Douglas ;
Eeles, Rosalind .
CLINICAL CANCER RESEARCH, 2006, 12 (23) :7033-7038